Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews.
You may also be interested in...
Sanofi/Regeneron’s Aflibercept Misses Mark In Phase II Ovarian Cancer Trial
Four Phase III studies underway in colorectal, pancreatic, prostate and lung cancer.
Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter
Follow-up ATHENA data bolsters NDA called “not approvable” in 2006.
Sanofi’s Lovenox Weathers Heparin Storm; Pipeline Faces Some Setbacks
Sanofi-Aventis' antithromboticLovenox is currently enjoying a bump from the fallout of the heparin scandal, with increased sales in the U.S. where the low molecular weight heparin is produced domestically. But it may be short-lived, as Momenta and Sandoz are gearing up to re-submit their ANDA for enoxaparin